Journal of Clinical Pharmacy and Therapeutics This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Dexmedetomidine as an adjuvant to 0.5% ropivacaine in ultrasound ‐guided axillary brachial plexus block
Summary What is known and objectiveThe aim of this study was to elucidate the effect of dexmedetomidine added to ropivacaine on the onset and duration of sensory and motor block and duration of analgesia of ultrasound‐guided axillary brachial plexus block. MethodsThirty‐seven ASA physical status I‐II patients with elective forearm and hand surgery under ultrasound‐guided axillary brachial plexus block were randomly divided into 2 groups. Patients in ropivacaine‐dexmedetomidine group (group RD, n = 19) received 15 mL of 0.5% ropivacaine with 100 μg (1 mL) dexmedetomidine, and patients in ropivacaine group (g...
Source: Journal of Clinical Pharmacy and Therapeutics - November 29, 2017 Category: Drugs & Pharmacology Authors: E. Koraki, C. Stachtari, I. Kapsokalyvas, Z. Stergiouda, A. Katsanevaki, A. Trikoupi Tags: ORIGINAL ARTICLE Source Type: research

Dexmedetomidine as an adjuvant to 0.5% ropivacaine in ultrasound ‐guided axillary brachial plexus block
Journal of Clinical Pharmacy and Therapeutics,Volume 43, Issue 3, Page 348-352, June 2018. (Source: Journal of Clinical Pharmacy and Therapeutics)
Source: Journal of Clinical Pharmacy and Therapeutics - November 28, 2017 Category: Drugs & Pharmacology Authors: E. Koraki MD , C. Stachtari MD, PhD , I. Kapsokalyvas MD , Z. Stergiouda MD , A. Katsanevaki MD , A. Trikoupi MD, PhD Source Type: research

Dexmedetomidine as an adjuvant to 0.5% ropivacaine in ultrasound ‐guided axillary brachial plexus block
Journal of Clinical Pharmacy and Therapeutics, EarlyView. (Source: Journal of Clinical Pharmacy and Therapeutics)
Source: Journal of Clinical Pharmacy and Therapeutics - November 28, 2017 Category: Drugs & Pharmacology Source Type: research

---
Journal of Clinical Pharmacy and Therapeutics, Ahead of Print. (Source: Journal of Clinical Pharmacy and Therapeutics)
Source: Journal of Clinical Pharmacy and Therapeutics - November 28, 2017 Category: Drugs & Pharmacology Source Type: research

The rapid ‐onset antidepressant effect of ketamine: More surprises?
Summary What is known and objectiveAn effective rapid‐onset treatment for major depressive disorder could save lives. Extensive preclinical and clinical data demonstrate such an action of ketamine. However, the presumptive mechanism of action, inhibition of NMDA (N‐methyl‐D‐aspartate) receptors, has recently been challenged. Elucidation of the mechanism is important clinically for drug discovery and for understanding the (patho)physiology of depression. CommentThe best‐known pharmacologic property of ketamine is non‐competitive inhibition of the NMDA subtype of glutamate receptor. Although other mechanisms have...
Source: Journal of Clinical Pharmacy and Therapeutics - November 27, 2017 Category: Drugs & Pharmacology Authors: R. B. Raffa, J. V. Pergolizzi, R. Taylor, Tags: COMMENTARY Source Type: research

The rapid ‐onset antidepressant effect of ketamine: More surprises?
Journal of Clinical Pharmacy and Therapeutics,Volume 43, Issue 2, Page 308-311, April 2018. (Source: Journal of Clinical Pharmacy and Therapeutics)
Source: Journal of Clinical Pharmacy and Therapeutics - November 26, 2017 Category: Drugs & Pharmacology Source Type: research

---
Journal of Clinical Pharmacy and Therapeutics,Volume 43, Issue 2, Page 308-311, April 2018. (Source: Journal of Clinical Pharmacy and Therapeutics)
Source: Journal of Clinical Pharmacy and Therapeutics - November 26, 2017 Category: Drugs & Pharmacology Source Type: research

Influence of genetic variants of IDH1, IDH2, TET2 and DNMT3A on cytarabine cytotoxicity in different populations
This study is aimed to explore the association between influence of genetic variants of IDH1, IDH2, TET2 and DNMT3A on cytarabine cytotoxicity in European and/or African populations. MethodsHapMap cell lines derived from European descent (CEU) and African descent (YRI) were exposed to ara‐C at different concentrations (1, 5, 40 and 80 μmol/L). The per cent survival values at each concentration were determined after 72‐hour exposure to ara‐C. The area under the survival curve (AUC) was calculated using the trapezoidal rule, and AUC values were log2‐transformed before statistical analysis. The 15 tagged single nucl...
Source: Journal of Clinical Pharmacy and Therapeutics - November 22, 2017 Category: Drugs & Pharmacology Authors: Y. Wang, J. K. Lamba Tags: ORIGINAL ARTICLE Source Type: research

Retracted: Influence of genetic variants of IDH1, IDH2, TET2 and DNMT3A on cytarabine cytotoxicity in different populations
Journal of Clinical Pharmacy and Therapeutics, EarlyView. (Source: Journal of Clinical Pharmacy and Therapeutics)
Source: Journal of Clinical Pharmacy and Therapeutics - November 21, 2017 Category: Drugs & Pharmacology Authors: Y. Wang , J. K. Lamba Source Type: research

---
Journal of Clinical Pharmacy and Therapeutics, Ahead of Print. (Source: Journal of Clinical Pharmacy and Therapeutics)
Source: Journal of Clinical Pharmacy and Therapeutics - November 21, 2017 Category: Drugs & Pharmacology Source Type: research

Retracted: Influence of genetic variants of IDH1, IDH2, TET2 and DNMT3A on cytarabine cytotoxicity in different populations
‘Influence of genetic variants of IDH1, IDH2, TET2 and DNMT3A on cytarabine cytotoxicity in different populations’ by Y. Wang & J. K. Lamba1 The above article from the Journal of Clinical Pharmacy and Therapeutics, published online on 21 November 2017 in Wiley Online Library (wileyonlinelibrary.com), has been retracted following discussions with the authors, the Journal Editors and John Wiley & Sons Ltd. The Retraction has been agreed as this paper was submitted under the joint names of Yan Wang, Jatinder K. Lamba and a third co‐author. After acceptance of the paper, Dr Wang wrote to the EiC asking for the na...
Source: Journal of Clinical Pharmacy and Therapeutics - November 21, 2017 Category: Drugs & Pharmacology Authors: Y. Wang, J. K. Lamba Tags: THIS ARTICLE HAS BEEN RETRACTED Source Type: research

Comparison of pharmacodynamic effects of ticagrelor vs prasugrel in type 2 diabetes mellitus patients with coronary heart disease
This study, involving 140 patients with T2DM following percutaneous coronary intervention (PCI), evaluated the efficacy of aspirin upon concomitant use of prasugrel (10 mg/d) or ticagrelor (90 mg/d). Platelet reactivity was assessed by value of ADP‐induced light transmittance aggregometry (LTA) and vasodilator‐stimulated phosphoprotein phosphorylation‐platelet reactivity index (VASP‐PRI) at baseline, 7 and 30 days after randomized P2Y12 inhibitor treatment. ResultsThe study showed a decreased platelet reactivity after use of P2Y12 inhibitors (both P < .001). On the basis of comparison between regimens, apar...
Source: Journal of Clinical Pharmacy and Therapeutics - November 18, 2017 Category: Drugs & Pharmacology Authors: L. ‐L. Shang, D.‐D. Guo, H.‐Y. Zhao, A.‐J. Quan, P.‐G. Cao Tags: ORIGINAL ARTICLE Source Type: research

Comparison of pharmacodynamic effects of ticagrelor vs prasugrel in type 2 diabetes mellitus patients with coronary heart disease
Journal of Clinical Pharmacy and Therapeutics,Volume 43, Issue 3, Page 342-347, June 2018. (Source: Journal of Clinical Pharmacy and Therapeutics)
Source: Journal of Clinical Pharmacy and Therapeutics - November 17, 2017 Category: Drugs & Pharmacology Authors: L. ‐L. Shang MD , D.‐D. Guo MD , H.‐Y. Zhao MD , A.‐J. Quan MD , P.‐G. Cao MD Source Type: research

Comparison of pharmacodynamic effects of ticagrelor vs prasugrel in type 2 diabetes mellitus patients with coronary heart disease
Journal of Clinical Pharmacy and Therapeutics, EarlyView. (Source: Journal of Clinical Pharmacy and Therapeutics)
Source: Journal of Clinical Pharmacy and Therapeutics - November 17, 2017 Category: Drugs & Pharmacology Source Type: research